<DOC>
	<DOCNO>NCT02532829</DOCNO>
	<brief_summary>The HIPER-1 study single centre cross sectional study total 240 participant ( different metabolic state surgical model ) receive Oral Mixed Meal Tolerance Test ( OMTT ) . At baseline 30 , 60 120 minute PYY level , GLP-1 level , glucose insulin sensitivity measure . The primary endpoint study area GLP-1 Peptide - YY curve insulin sensitivity follow OMTT .</brief_summary>
	<brief_title>Human Intestinal Peptides Evaluation Research</brief_title>
	<detailed_description>Obesity type 2 diabetes mellitus ( T2DM ) increase worldwide , thus reach pandemic proportion . Diet , exercise medication remain cornerstone type 2 diabetes mellitus treatment . But , apart study demonstrate promising result develop country ; long-term success rate lifestyle drug modification disappoint . In case classic strategy prove inadequate , broad type gastrointestinal ( GI ) surgery method offer new alternative treat obesity T2DM . The variable level incretin stimulation ( especially GLP-1 ) improve glycaemic control diabetes show follow various bariatric technique . Therefore , investigator aim analyze level GLP-1 Peptide YY hormones together index insulin sensitivity participant various health condition participants underwent different surgical option include sleeve gastrectomy , minigastric bypass , sleeve gastrectomy ileal transposition sleeve gastrectomy transit bipartition .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>For NONSURGERY GROUPS 1 . GROUP NSA : Healthy participant , know disease , previous surgery , HbA1c &lt; 5.7 % , BMI &lt; 25 kg/m2 ( n=30 ) . GROUP NSB : Obese diabetic , type 2 diabetes diagnosis longer 3 year ; BMI &gt; 30 kg/m2 ( n=30 ) . GROUP NSC : Nonobese diabetic , type 2 diabetes diagnosis longer 3 year ; BMI &lt; 30 kg/m2 ( n=30 ) . GROUP NSD : Obese nondiabetics , HbA1c &lt; 5.7 % , No sign history T2D , BMI &gt; 30 kg/m2 ( n=30 ) . 2 . Preferably kind antidiabetic drug accept cessation antidiabetic drug 2 day prior evaluation . 3 . Absence comorbidities ( dyslipidemia , hypertension , neuropathy , retinopathy , cardiovascular disease , stroke event low extremity amputation ) . 4 . Possibility participate quadruplicate measurement protocol . 1 . Anti insulin / islet antibody glutamic acid decarboxylase antibody ( antiGAD ) positivity , plasma fast Cpeptide less 1 ng/ml . 2 . Liver cirrhosis , severe renal failure , collagen disease , severe endocrinopathies , blindness . 3 . Heart failure , acute myocardial infarction , stroke transient ischemic attack , unstable angina pectoris . 4 . History malignancy malignant neoplasm place , severe inflammatory complication , neurological cardiovascular act . 5 . Pregnancy 6 . Any condition discretion head study represent risk participant could affect protocol result . For SURGERY GROUPS 1 . Type 2 Diabetic participant underwent sleeve gastrectomy , minigastric bypass , sleeve gastrectomy ileal transposition sleeve gastrectomy transit bipartition perform 6 month ago , within last 2 year , steady weight profile . 2 . Preferably kind antidiabetic drug accept cessation antidiabetic drug 2 day prior evaluation . 3 . Absence resolve comorbidities ( dyslipidemia , hypertension , neuropathy , retinopathy , cardiovascular disease , stroke event low extremity amputation ) . 4 . Possibility participate quadruplicate measurement protocol . 1 . Liver cirrhosis , severe renal failure , collagen disease , severe endocrinopathies , blindness . 2 . Heart failure , acute myocardial infarction , stroke transient ischemic attack , unstable angina pectoris . 3 . History malignancy malignant neoplasm place , severe inflammatory complication , neurological cardiovascular act . 4 . Pregnancy 5 . Any condition discretion head study represent risk participant could affect protocol result .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>